Samchundang Pharmaceutical Drops from "Emperor Stock" Status Amid Plunge... Announces Legal Action Over Blog-Based Stock Manipulation Allegations
Refutes Claims of "Speculative Stock Manipulation"
Clarifies Contract Size Amid Controversy
Samchundang Pharmaceutical, a large-cap company listed on the KOSDAQ market, saw its shares plummet, while the company announced plans to take strong legal action against allegations of stock price manipulation that have surfaced online.
On March 31, Samchundang Pharmaceutical announced on its official website that "a particular blogger is causing market confusion with baseless posts such as 'operation stock' and 'blatant stock price manipulation,'" and stated the company would file complaints for defamation and obstruction of business. Blogger A raised suspicions about Samchundang Pharmaceutical's stock price movements in a post on March 30, referencing the company's main business activities and contract processes.
The company also objected to the analysis of a specific analyst. "We have strongly protested to the analyst who distributed a post suggesting that additional clinical trials are necessary for generic drug registration," the company said, emphasizing that "we will consider legal action against any posts made without factual verification."
Samchundang Pharmaceutical's share price had previously surged rapidly due to high expectations for its oral insulin platform and development of GLP-1 (glucagon-like peptide-1) class obesity and diabetes treatments. At the beginning of this year, the company's market capitalization was around 5 trillion won, but it soared to the 20 trillion won range in a short period.
However, investment sentiment deteriorated sharply as the contract details disclosed the previous day were seen as falling short of market expectations. Although the company announced that it had signed an exclusive contract related to oral semaglutide in the U.S. market, there was criticism that the disclosed contract value was smaller than anticipated.
Samchundang Pharmaceutical explained, "The 150 billion won reported as the contract amount is only a milestone payment," adding, "Actual sales are expected to reach approximately 15 trillion won during the contract period by the partner company, and Samchundang will receive 90% of the net profit from these sales."
Despite the company’s decision to file a complaint, Blogger A responded with an additional post, saying, "If a company can collapse over such a post, that is an even bigger problem," and added, "If you report me, I will go all the way."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Samchundang Pharmaceutical, which had entered the so-called "Emperor Stock" category by closing at 1,115,000 won on March 25, climbed to 1,184,000 won the previous day, but then plunged 29.98% in a single day to close at 829,000 won.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.